Novartis Data Reveals Significant LDL-C Reduction With Early Addition Of Leqvio In ASCVD Patients

(RTTNews) - Novartis (NVS) announced new data demonstrating the early addition of twice-yearly Leqvio (inclisiran) to maximally tolerated statin therapy, prior to guideline-recommended ezetimibe, in a real-world setting significantly reduced low-density lipoprotein cholesterol (LDL-C) in patients with atherosclerotic cardiovascular disease or ASCVD, including those with a history of an ASCVD-related event, who could not reach their goal on statin therapy alone.

In the V-INITIATE study, patients receiving Leqvio experienced significant reductions in LDL-C compared to those receiving usual care (60% vs. 7%, respectively), which consisted mostly of statin therapy alone (73%).

The company noted that a significantly greater proportion of the ASCVD patients receiving Leqvio achieved guideline-recommended LDL-C goal vs. the usual care arm while maintaining adherence to statin treatment.

Results from usual care arm reinforced the urgent need for more aggressive LDL-C lowering in ASCVD patients, 92% of whom did not reach their LDL-C goal with statins alone.

According to the company, the Leqvio safety profile was consistent with the Phase III clinical studies and long-term open-label extension trials for up to 6 years of treatment.

For More Such Health News, visit rttnews.com.